Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy

Clinical Infectious Diseases

Volumn 29, Issue 1, 1999, Pages 75-81

  Clough, Lisa A ^a   D'Agata, Erika ^a   Raffanti, Stephen ^a   Haas, David W ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NARCOTIC AGENT; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; VIROLOGY;

EID: 0032771575     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520185     Document Type: Article

References (24)

1. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
2. 2. Moss AR, Bacchetti P. Natural history of HIV infection. AIDS 1989;3:55-61.
3. 3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33.
4. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-38.
5. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
6. 6. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
7. 7. Saag M, Gersten M, Chang Y, Greenberg SL, Yu G, Clendeninn NJ. Long term virological and immunological effect of the HIV protease inhibitor, VIRACEPT (nelfinavir mesylate, NFV) in combination with zidovudine (AZT) and lamivudine (3TC) [abstract no 221]. Clin Infect Dis 1997;25:396.
8. 8. Saimot AG, Landman R, Damond F, et al. Ritonavir, slavudine, didanosine as a triple combination treatment in antiretroviral naive patients (abstract no 246). In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, Virginia: IDSA for Foundation for Retrovirology and Human Health, 1997.
9. 9. Mathez D, Barnarelli P, de Truchis P, et al. A triple combination of ritonavir + AZT + DDC as a first line treatment of patients with AIDS: update (abstract no Mo.B.175). In: Program and abstracts of the XI International Conference on AIDS (Vancouver, British Columbia, Canada). Vancouver: XI International Conference on AIDS Society, 1996.
10. 10. Pednaull L, Elion R, Adler M, et al. Stavudine, didanosine, and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study (abstract no 241). In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, Virginia: IDSA for Foundation for Retrovirology and Human Health, 1997.
11. 11. Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologic failure to indinavir or/and ritonavir in an urban clinic (abstract LB-2). In: Program and abstracts of the 37th Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
12. 12. Condra J, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
13. 13. Schmit J-C, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir. AIDS 1996;10:995-9.
14. 14. Zhang Y-M, Imanichi H, Falloon J, et al. Emergence of drug resistant HIV variants with mutations in the protease gene and gag cleavage sites during indinavir therapy (abstract no 602). In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, Virginia: IDSA for Foundation for Retrovirology and Human Health, 1997.
15. 15. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.
16. 16. Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combination against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996;173:355-64.
17. 17. Havlir DV, Friedland G, Pollard R, et al. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleosides: report of two randomized trials (ACTG 290 and 298) (abstract no 2). In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1998.
18. 18. Demeter L, Hughes M, Fischl M, et al. Predictors of virologic and clinical response to indinavir (IDV) + ZDV + 3TC or ZDV + 3TC (abstract no 509). In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1998.
19. 19. Garbe J, Buck J, Hammerling U. Retinoids are important cofactors in T cell activation. J Exp Med 1992;176:109-17.
20. 20. Wang W, Napoli JL, Ballow M. The effects of retinol on in vitro immunoglobulin synthesis by cord blood and adult peripheral blood mononuclear cells. Clin Exp Immunol 1993;92:164-8.
21. 21. Des Jarlais DC, Friedman SR. HIV and intravenous drug use. AIDS 1988;2(suppl 1):S65-9.
22. 22. Kaslow RA, Blackwelder WC, Ostrow DG, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1 positive individuals. JAMA 1989;261:3424-9.
23. 23. Schechter MT, Craib KJP, Thinh NL, et al. Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men. AIDS 1989;3:347-53.
24. 24. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-6.